Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 2/2019

01-06-2019 | Obesity

Prolactin and human weight disturbances: A puzzling and neglected association

Authors: Luis G. Sobrinho, Nelson D. Horseman

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 2/2019

Login to get access

Abstract

Weight gain at the outset of prolactinomas in many women is well documented. Yet, this symptom is absent from the clinical descriptions of the disease in textbooks and reviews. This omission is almost certainly due to the absence of a physiological explanation for the phenomenon, as prolactin is not a recognized fat promoting hormone. In this review we present the clinical evidence for a relationship between prolactin and fat accumulation and address some possible mechanisms involved. We put forward the hypothesis that prolactin is a component of a neuroendocrine program – maternal subroutine – aimed at optimizing the care of the young through the production of milk, promotion of maternal behavior and increase in the metabolic efficiency of the mother. These adaptations can enable her to face the extraordinary metabolic expenses of pregnancy and nursing, especially during times of suboptimal environmental conditions. We emphasize the uniqueness of prolactin in that it is a hormone that is tonically inhibited and which has its major effects on the regulation of an inter-individual (the mother – offspring dyad), rather than an intra-individual, system. This approach opens a window to consider the possibility of external events as regulators of this system. It also allows addressing a variety of hitherto unexplained findings reported in the literature. Examples include: association of prolactinomas with paternal deprivation and with stressful life events; pseudocyesis; acute life event-driven episodes of galactorrhea; episodes of rapid weight gain following a life event; prolactin surges (without associated cortisol surges) following some psychological stresses.
Literature
1.
go back to reference Forbes AP, Henneman PH, Griswold GC, Albright F. Syndrome characterized by galactorrhea, amenorrhea and low urinary FSH: comparison with acromegaly and normal lactation. J Clin Endocrinol Metab. 1954;14:265–71.CrossRefPubMed Forbes AP, Henneman PH, Griswold GC, Albright F. Syndrome characterized by galactorrhea, amenorrhea and low urinary FSH: comparison with acromegaly and normal lactation. J Clin Endocrinol Metab. 1954;14:265–71.CrossRefPubMed
2.
go back to reference Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2009;12:96–104.CrossRefPubMed Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2009;12:96–104.CrossRefPubMed
3.
go back to reference Nunes MC, Sobrinho LG, Calhaz-Jorge C, Santos MA, Mauricio JC, Sousa MF. Psychosomatic factors in patients with hyperprolactinemia and/or galactorrhea. Obstet Gynecol. 1980;55:591–5.PubMed Nunes MC, Sobrinho LG, Calhaz-Jorge C, Santos MA, Mauricio JC, Sousa MF. Psychosomatic factors in patients with hyperprolactinemia and/or galactorrhea. Obstet Gynecol. 1980;55:591–5.PubMed
4.
go back to reference Gould BK, Randall RV, Kempers RD, Ryan RJ. Galactorrhoea. Springfield. Ill: CC Thomas; 1974. Gould BK, Randall RV, Kempers RD, Ryan RJ. Galactorrhoea. Springfield. Ill: CC Thomas; 1974.
5.
go back to reference Galluzzi F, Salti R, Stagi S, La Cauza F, Chiarelli F. Reversible weight gain and prolactin levels -long-term follow-up in childhood. Journal Ped Endocrinol Metabol. 2005;18:921–4.CrossRef Galluzzi F, Salti R, Stagi S, La Cauza F, Chiarelli F. Reversible weight gain and prolactin levels -long-term follow-up in childhood. Journal Ped Endocrinol Metabol. 2005;18:921–4.CrossRef
6.
go back to reference Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP. Prolactinoma and body weight: a retrospective study. Acta Endocrinol. 1991;125:392–6.CrossRef Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP. Prolactinoma and body weight: a retrospective study. Acta Endocrinol. 1991;125:392–6.CrossRef
7.
go back to reference Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol. 1998;48:547–53.CrossRef Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol. 1998;48:547–53.CrossRef
8.
go back to reference Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Di Somma C, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148:325–31.CrossRefPubMed Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Di Somma C, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148:325–31.CrossRefPubMed
9.
go back to reference Wallace RB, Sherman BM, Bean JA. Clinical and biological antecedents of the amenorrhea/hyperprolactinemia syndrome: a case control study. Fertil Steril. 1985;43:726–32.CrossRefPubMed Wallace RB, Sherman BM, Bean JA. Clinical and biological antecedents of the amenorrhea/hyperprolactinemia syndrome: a case control study. Fertil Steril. 1985;43:726–32.CrossRefPubMed
10.
go back to reference Schmid C, Goede DL, Hauser RS, Brändle M. Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006;136:254–8.PubMed Schmid C, Goede DL, Hauser RS, Brändle M. Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006;136:254–8.PubMed
11.
go back to reference Cohen LM, Greenberg DB, Murray GB. Neuropsychiatric presentation of men with pituitary tumors (the “four as”). Psychosomatics. 1984;25:925–8.CrossRefPubMed Cohen LM, Greenberg DB, Murray GB. Neuropsychiatric presentation of men with pituitary tumors (the “four as”). Psychosomatics. 1984;25:925–8.CrossRefPubMed
12.
go back to reference Naliato ECO, Violante AHD, Gaccione M, Caldas D, Lamounier Filho A, Loureiro CR, et al. Body fat in men with prolactinoma. J Endocrinol Investig. 2008;31:985–90.CrossRef Naliato ECO, Violante AHD, Gaccione M, Caldas D, Lamounier Filho A, Loureiro CR, et al. Body fat in men with prolactinoma. J Endocrinol Investig. 2008;31:985–90.CrossRef
13.
go back to reference Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147:77–84.CrossRefPubMed Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147:77–84.CrossRefPubMed
14.
go back to reference Pala NA, Misgar LBARA, RA RDA. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr. 2015;7:99.CrossRefPubMedPubMedCentral Pala NA, Misgar LBARA, RA RDA. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr. 2015;7:99.CrossRefPubMedPubMedCentral
15.
go back to reference Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol 2006;64:366–70. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol 2006;64:366–70.
16.
go back to reference Bronstein, M.D. Disorders of prolactin secretion and prolactinomas. in Jameson, J. L. and L. J. DeGroot editors, Endocrinology: Adult and Pediatric. Saunders, Philadelphia, PA. 2016. vol. 1. pp. 333–57. Bronstein, M.D. Disorders of prolactin secretion and prolactinomas. in Jameson, J. L. and L. J. DeGroot editors, Endocrinology: Adult and Pediatric. Saunders, Philadelphia, PA. 2016. vol. 1. pp. 333–57.
17.
go back to reference Matsuda M, Imaoka T, Vomachka AJ, Gudelsky GA, Hou Z, Mistry M, et al. Serotonin regulates mammary gland development via an autocrine-paracrine loop. Dev Cell. 2004;6:193–203.CrossRefPubMed Matsuda M, Imaoka T, Vomachka AJ, Gudelsky GA, Hou Z, Mistry M, et al. Serotonin regulates mammary gland development via an autocrine-paracrine loop. Dev Cell. 2004;6:193–203.CrossRefPubMed
18.
go back to reference Stull MA, Pai V, Vomachka AJ, Marshall AM, Jacob GA, Horseman ND. Mammary gland homeostasis employs serotonergic regulation of epithelial tight junctions. Proc Natl Acad Sci U S A. 2007;104:16708–13.CrossRefPubMedPubMedCentral Stull MA, Pai V, Vomachka AJ, Marshall AM, Jacob GA, Horseman ND. Mammary gland homeostasis employs serotonergic regulation of epithelial tight junctions. Proc Natl Acad Sci U S A. 2007;104:16708–13.CrossRefPubMedPubMedCentral
19.
go back to reference Hernandez LL, Gregerson KA, Horseman ND. Mammary gland serotonin regulates parathyroid hormone-related peptide and other bone-related signals. Am J Physiol Endocrinol Metab. 2012;302:E1009–15.CrossRefPubMedPubMedCentral Hernandez LL, Gregerson KA, Horseman ND. Mammary gland serotonin regulates parathyroid hormone-related peptide and other bone-related signals. Am J Physiol Endocrinol Metab. 2012;302:E1009–15.CrossRefPubMedPubMedCentral
20.
go back to reference Horseman ND, Hernandez LL. New concepts of breast cell communication to bone. Trends Endocrinol Metabol. 2014;25:34–41.CrossRef Horseman ND, Hernandez LL. New concepts of breast cell communication to bone. Trends Endocrinol Metabol. 2014;25:34–41.CrossRef
21.
go back to reference Kovacs CS, Chik CL. Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium phosphate parathyroid hormone (PTH) and PTH-related peptide levels. J Clin Endocrinol Metab. 1995;80:3036–42.PubMed Kovacs CS, Chik CL. Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium phosphate parathyroid hormone (PTH) and PTH-related peptide levels. J Clin Endocrinol Metab. 1995;80:3036–42.PubMed
22.
go back to reference Stiegler C, Leb G, Kleinert R, Warnkross H, Ramschak-Schwarzer S, Lipp R, et al. Plasma levels of parathyroid hormone-related peptide are elevated in hyperprolactinemia and correlated to bone density status. J Bone Mineral Res. 1995;10:751–9.CrossRef Stiegler C, Leb G, Kleinert R, Warnkross H, Ramschak-Schwarzer S, Lipp R, et al. Plasma levels of parathyroid hormone-related peptide are elevated in hyperprolactinemia and correlated to bone density status. J Bone Mineral Res. 1995;10:751–9.CrossRef
23.
go back to reference Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami H, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nature Med. 2010;16:804–8.CrossRefPubMed Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami H, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nature Med. 2010;16:804–8.CrossRefPubMed
24.
go back to reference Baeyens L, Hindi S, Sorenson RL, German MS. β-Cell adaptation in pregnancy. Diabetes, Obesity and Metabol. 2016;18:63–70.CrossRef Baeyens L, Hindi S, Sorenson RL, German MS. β-Cell adaptation in pregnancy. Diabetes, Obesity and Metabol. 2016;18:63–70.CrossRef
25.
go back to reference Sobrinho LG. Neuropsychiatry of prolactin: causes and effects. Ballière's. Clin Endocrinol Metab. 1991;5:119–41. Sobrinho LG. Neuropsychiatry of prolactin: causes and effects. Ballière's. Clin Endocrinol Metab. 1991;5:119–41.
26.
go back to reference Del Pizzo J, Posey-Bahar L, Jimenez R. Pseudocyesis in a teenager with bipolar disorder. Clin Pediatr (Phila). 2011;50:169–71.CrossRef Del Pizzo J, Posey-Bahar L, Jimenez R. Pseudocyesis in a teenager with bipolar disorder. Clin Pediatr (Phila). 2011;50:169–71.CrossRef
28.
go back to reference Zarate A, Canales ES, Soria J, Jacobs LS, Daughaday WH, Kastin AJ, et al. Gonadotropin and prolactin secretion in human pseudocyesis. Annales d’Endocrinologe (Paris). 1974;35:445–50. Zarate A, Canales ES, Soria J, Jacobs LS, Daughaday WH, Kastin AJ, et al. Gonadotropin and prolactin secretion in human pseudocyesis. Annales d’Endocrinologe (Paris). 1974;35:445–50.
29.
go back to reference Yen SSC, Rebar RW, Quesenberry W. Pituitary function in pseudocyesis. J Clin Endocrinol Metab. 1976;43:132–6.CrossRefPubMed Yen SSC, Rebar RW, Quesenberry W. Pituitary function in pseudocyesis. J Clin Endocrinol Metab. 1976;43:132–6.CrossRefPubMed
30.
go back to reference Osotimehin BO, Ladipo OA, Adejuwon CA. Otolorin EO (1981) pituitary and placental hormone levels in pseudocyesis. Int J Gynaecol Obstet. 1981;19:399–402.CrossRefPubMed Osotimehin BO, Ladipo OA, Adejuwon CA. Otolorin EO (1981) pituitary and placental hormone levels in pseudocyesis. Int J Gynaecol Obstet. 1981;19:399–402.CrossRefPubMed
31.
go back to reference Tulandi T, McInnes RA, Lal S. Altered pituitary hormone secretion in patients with pseudocyesis. Fertil Steril. 1983;40:637–41.CrossRefPubMed Tulandi T, McInnes RA, Lal S. Altered pituitary hormone secretion in patients with pseudocyesis. Fertil Steril. 1983;40:637–41.CrossRefPubMed
32.
go back to reference Devane GW, Vera MI, Buhl WC, Kalra PS. Opioid peptides in pseudocyesis. Obstet Gynecol. 1985;65:183–8.PubMed Devane GW, Vera MI, Buhl WC, Kalra PS. Opioid peptides in pseudocyesis. Obstet Gynecol. 1985;65:183–8.PubMed
33.
go back to reference Starkman MN, Marshall JC, La Ferla J, Kelch RP. Pseudocyesis: psychologic and neuroendocrine interrelationships. Psychosom Med. 1985;47:46–57.CrossRefPubMed Starkman MN, Marshall JC, La Ferla J, Kelch RP. Pseudocyesis: psychologic and neuroendocrine interrelationships. Psychosom Med. 1985;47:46–57.CrossRefPubMed
34.
go back to reference Forsbach G, Güitron A, Munoz M, Bustos H. Pituitary function in human pseudocyesis. J Endocrinol Investig. 1987;10:39–43.CrossRef Forsbach G, Güitron A, Munoz M, Bustos H. Pituitary function in human pseudocyesis. J Endocrinol Investig. 1987;10:39–43.CrossRef
35.
go back to reference Bray MA, Muneyyirci-Delale O, Kofinas GD, Reyes FI. Circadian, ultradian and episodic gonadotropin and prolactin secretion in human pseudocyesis. Acta Endocrinol. 1991;124:501–9.CrossRef Bray MA, Muneyyirci-Delale O, Kofinas GD, Reyes FI. Circadian, ultradian and episodic gonadotropin and prolactin secretion in human pseudocyesis. Acta Endocrinol. 1991;124:501–9.CrossRef
36.
go back to reference Padayachi T, Ashe R, Moodley J, Jialal I. Pituitary function tests in black patients with pseudocyesis. S Afr Med J. 1991;79:24–6.PubMed Padayachi T, Ashe R, Moodley J, Jialal I. Pituitary function tests in black patients with pseudocyesis. S Afr Med J. 1991;79:24–6.PubMed
37.
go back to reference Copinschi G, De Laet MH, Brion JP, Leclerc R, L’Hermite M, Robyn C, et al. Simultaneous study of cortisol, growth hormone and prolactin nyctohemeral variations in normal and obese subjects influence of prolonged fasting in obesity. Clin Endocrinol. 1978;9:15–26.CrossRef Copinschi G, De Laet MH, Brion JP, Leclerc R, L’Hermite M, Robyn C, et al. Simultaneous study of cortisol, growth hormone and prolactin nyctohemeral variations in normal and obese subjects influence of prolonged fasting in obesity. Clin Endocrinol. 1978;9:15–26.CrossRef
38.
go back to reference Kok P, Roelfsma F, Frőlich M, Meinders AE, Pijl H. 2004. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab. 2004;89:4445–9.CrossRefPubMed Kok P, Roelfsma F, Frőlich M, Meinders AE, Pijl H. 2004. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab. 2004;89:4445–9.CrossRefPubMed
39.
go back to reference Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, et al. The relationship between blood prolactin levels and risk of breast cancer in premenopausal women. Eur J Cancer Clin Oncol. 1987;23:1541–8.CrossRefPubMed Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, et al. The relationship between blood prolactin levels and risk of breast cancer in premenopausal women. Eur J Cancer Clin Oncol. 1987;23:1541–8.CrossRefPubMed
40.
go back to reference Kok P, Roelfsema F, Langendonk JG, de Wit CC, Frőlich M, Burggraaf J, et al. Am J Physiol Endocrinol Metab. 2006;90:E218–24.CrossRef Kok P, Roelfsema F, Langendonk JG, de Wit CC, Frőlich M, Burggraaf J, et al. Am J Physiol Endocrinol Metab. 2006;90:E218–24.CrossRef
41.
go back to reference Ben-Jonathan N, Hugo E. Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol. 2015;846:1–35.CrossRefPubMed Ben-Jonathan N, Hugo E. Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol. 2015;846:1–35.CrossRefPubMed
42.
go back to reference Ferreira MF, Sobrinho LG, Pires JS, Silva MES, Santos MA, Sousa MFF. Endocrine and psychological evaluation of women with recent weight gain. Psychoneuroendocrinology. 1995;20:53–63.CrossRefPubMed Ferreira MF, Sobrinho LG, Pires JS, Silva MES, Santos MA, Sousa MFF. Endocrine and psychological evaluation of women with recent weight gain. Psychoneuroendocrinology. 1995;20:53–63.CrossRefPubMed
43.
go back to reference Paykel ES. Methodological aspects of life events research. Adv Psychosomatic Med. 1987;17:13–29.CrossRef Paykel ES. Methodological aspects of life events research. Adv Psychosomatic Med. 1987;17:13–29.CrossRef
44.
go back to reference Sobrinho L. The psychosomatic interface: hyperprolactinemia. In: Horseman ND, editor. Prolactin. Boston: Kluwer Academic Publishers; 2001. Sobrinho L. The psychosomatic interface: hyperprolactinemia. In: Horseman ND, editor. Prolactin. Boston: Kluwer Academic Publishers; 2001.
45.
go back to reference Baptista T, La Cruz A, Meza T, Contreras Q, Delgado C, Mejìas MA, et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatr. 2001;46:829–34.CrossRef Baptista T, La Cruz A, Meza T, Contreras Q, Delgado C, Mejìas MA, et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatr. 2001;46:829–34.CrossRef
46.
go back to reference Yang F, Chen L, Fang X, Zheng K, Zhu C, Xu C, et al. Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia. Neuropsychiatr Dis Treat. 2018;14:3373–9.CrossRefPubMedPubMedCentral Yang F, Chen L, Fang X, Zheng K, Zhu C, Xu C, et al. Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia. Neuropsychiatr Dis Treat. 2018;14:3373–9.CrossRefPubMedPubMedCentral
47.
go back to reference Neovius M, Eberhard J, Lindström E, Levander S. Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatr Scand. 2007;115:277–85.CrossRefPubMed Neovius M, Eberhard J, Lindström E, Levander S. Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatr Scand. 2007;115:277–85.CrossRefPubMed
48.
go back to reference Baptista T1, Parada M. Hernandez LLong term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav. 1987;27:399–405.CrossRefPubMed Baptista T1, Parada M. Hernandez LLong term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav. 1987;27:399–405.CrossRefPubMed
49.
go back to reference Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and toler-ability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMed Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and toler-ability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMed
50.
go back to reference Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017;127:3402–6.CrossRefPubMedPubMedCentral Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017;127:3402–6.CrossRefPubMedPubMedCentral
51.
go back to reference Baptista T, Contreras Q, Teneud L, Albornoz MA, Acosta A, Páez X, et al. Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 1998;22:187–9.CrossRef Baptista T, Contreras Q, Teneud L, Albornoz MA, Acosta A, Páez X, et al. Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 1998;22:187–9.CrossRef
52.
go back to reference Kopchick, J.J, G.A. Martos-Moreno, M. Korbonits, B. D. Gaylinn, R. Nass, and M. O. Thorner.. Regulation of Growth Hormone and Actions (Secretagogues). in Jameson, J. L. and L. J. DeGroot editors, "Endocrinology: Adult and Pediatric" Saunders, Philadelphia, PA. 2016. vol. 1. pp. 412–53. Kopchick, J.J, G.A. Martos-Moreno, M. Korbonits, B. D. Gaylinn, R. Nass, and M. O. Thorner.. Regulation of Growth Hormone and Actions (Secretagogues). in Jameson, J. L. and L. J. DeGroot editors, "Endocrinology: Adult and Pediatric" Saunders, Philadelphia, PA. 2016. vol. 1. pp. 412–53.
53.
go back to reference Wang, S., J. Wu, N. Wang, L. Zeng and Y. Wu 2017 The role of growth hormone receptor in ß cell function. Growth Hormon IGF Res 56:30–35. Wang, S., J. Wu, N. Wang, L. Zeng and Y. Wu 2017 The role of growth hormone receptor in ß cell function. Growth Hormon IGF Res 56:30–35.
54.
go back to reference Daimon M, Kamba A, Murakami H, Mizushiri S, Osonoi S, Yamaichi M, et al. Association between serum prolactin levels and insulin resistance in non-diabetic men. PLoS One. 2017;12:e0175204.CrossRefPubMedPubMedCentral Daimon M, Kamba A, Murakami H, Mizushiri S, Osonoi S, Yamaichi M, et al. Association between serum prolactin levels and insulin resistance in non-diabetic men. PLoS One. 2017;12:e0175204.CrossRefPubMedPubMedCentral
55.
go back to reference Illingworth PJ, Jung RT, Howie PW, Leslie P, Isles TE. Diminution of energy expenditure during lactation. Brit Med J. 1986;292:437–41.CrossRef Illingworth PJ, Jung RT, Howie PW, Leslie P, Isles TE. Diminution of energy expenditure during lactation. Brit Med J. 1986;292:437–41.CrossRef
56.
go back to reference Lunn PG, Austin S, Prentice AM, Whitehead RG. Influence of maternal diet on plasma prolactin levels during lactation. Lancet. 1980;1:623–5.CrossRefPubMed Lunn PG, Austin S, Prentice AM, Whitehead RG. Influence of maternal diet on plasma prolactin levels during lactation. Lancet. 1980;1:623–5.CrossRefPubMed
57.
go back to reference Christensen HR, Murawsky MK, Horseman ND, Willson TA, Gregerson KA. Completely humanizing prolactin rescues infertility in prolactin knockout mice and leads to human prolactin expression in extrapituitary mouse tissues. Endocrinology. 2013;154:4777–89.CrossRefPubMedPubMedCentral Christensen HR, Murawsky MK, Horseman ND, Willson TA, Gregerson KA. Completely humanizing prolactin rescues infertility in prolactin knockout mice and leads to human prolactin expression in extrapituitary mouse tissues. Endocrinology. 2013;154:4777–89.CrossRefPubMedPubMedCentral
58.
go back to reference Marano RJ, Ben-Jonathan N. Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol. 2014;28(5):622–33.CrossRefPubMedPubMedCentral Marano RJ, Ben-Jonathan N. Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol. 2014;28(5):622–33.CrossRefPubMedPubMedCentral
59.
go back to reference Nagaishi VS, Cardinali LI, Zampieri TT, Furigo IC, Metzger M, Donato J Jr. Possible crosstalk between leptin and prolactin during pregnancy. Neuroscience. 2014;259:71–83.CrossRefPubMed Nagaishi VS, Cardinali LI, Zampieri TT, Furigo IC, Metzger M, Donato J Jr. Possible crosstalk between leptin and prolactin during pregnancy. Neuroscience. 2014;259:71–83.CrossRefPubMed
60.
go back to reference Jürgensen O, Bardé B. Psychodynamic findings in women with elevated prolactin. In the Yooung Woman. Eds. Dennerstein L, De Senarclens M. Excerpta Médica, International Congress Series, 618, Amsterdam-Oxford–Princeton. 1983, pp 138–148. Jürgensen O, Bardé B. Psychodynamic findings in women with elevated prolactin. In the Yooung Woman. Eds. Dennerstein L, De Senarclens M. Excerpta Médica, International Congress Series, 618, Amsterdam-Oxford–Princeton. 1983, pp 138–148.
61.
go back to reference Assies J, Vingerhoets AJ, Poppelaars K. (1992) psychosocial aspects of hyperprolactinemia. Psychoneuroendocrinology. 1992;17:673–9.CrossRefPubMed Assies J, Vingerhoets AJ, Poppelaars K. (1992) psychosocial aspects of hyperprolactinemia. Psychoneuroendocrinology. 1992;17:673–9.CrossRefPubMed
62.
go back to reference Rojas LM, Sthory I, Canales ES, Zárate A. Factores psicogénicos en el síndroma de amenorrea-galactorrea. Ginecol Obstet Mex. 1981;49:291–5.PubMed Rojas LM, Sthory I, Canales ES, Zárate A. Factores psicogénicos en el síndroma de amenorrea-galactorrea. Ginecol Obstet Mex. 1981;49:291–5.PubMed
63.
go back to reference Sobrinho LG, Duarte JS, Paiva I, Gomes L, Vicente V, Aguiar P. Paternal deprivation prior to adolescence and vulnerability to pituitary adenomas. Pituitary. 2012;15:251–7.CrossRefPubMed Sobrinho LG, Duarte JS, Paiva I, Gomes L, Vicente V, Aguiar P. Paternal deprivation prior to adolescence and vulnerability to pituitary adenomas. Pituitary. 2012;15:251–7.CrossRefPubMed
64.
go back to reference Sonino N, Navarrini C, Ruini C, Fallo F, Boscaro M, Fava GA. Life events in the pathogenesis of hyperprolactinemia. European J Endocrinol. 2004;151:61–5.CrossRef Sonino N, Navarrini C, Ruini C, Fallo F, Boscaro M, Fava GA. Life events in the pathogenesis of hyperprolactinemia. European J Endocrinol. 2004;151:61–5.CrossRef
65.
go back to reference Ma W, Ikeda H, Yoshimoto T. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer. 2002;95:258–66.CrossRefPubMed Ma W, Ikeda H, Yoshimoto T. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer. 2002;95:258–66.CrossRefPubMed
66.
go back to reference Burrow GN, Wortzman G, Rewcastle RB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med. 1981;304:156:8.CrossRefPubMed Burrow GN, Wortzman G, Rewcastle RB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med. 1981;304:156:8.CrossRefPubMed
67.
go back to reference Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613–9.CrossRefPubMed Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613–9.CrossRefPubMed
68.
go back to reference Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol. 2006;154:753–8.CrossRefPubMed Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol. 2006;154:753–8.CrossRefPubMed
69.
go back to reference Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Althoff PH, et al. Pituitary Corticotroph adenoma in a woman with long-standing Addison's disease: a histologic, Immunocytochemical, Electron microscopic, and in situ hybridization study. Endocr Pathol. 1996;7:91–7.CrossRefPubMed Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Althoff PH, et al. Pituitary Corticotroph adenoma in a woman with long-standing Addison's disease: a histologic, Immunocytochemical, Electron microscopic, and in situ hybridization study. Endocr Pathol. 1996;7:91–7.CrossRefPubMed
70.
go back to reference Kleinberg D. Pituitary tumors and failure of endocrine target organs. Arch Intern Med. 1979;139:969–70.CrossRefPubMed Kleinberg D. Pituitary tumors and failure of endocrine target organs. Arch Intern Med. 1979;139:969–70.CrossRefPubMed
71.
go back to reference Nicolis G, Shimshi M, Allen C, Halmi NS, Kourides IA. Gonadotropin-producing pituitary adenoma in a man with long-standing primary hypogonadism. J Clin Endocrinol Metab. 1988;66:237–41.CrossRefPubMed Nicolis G, Shimshi M, Allen C, Halmi NS, Kourides IA. Gonadotropin-producing pituitary adenoma in a man with long-standing primary hypogonadism. J Clin Endocrinol Metab. 1988;66:237–41.CrossRefPubMed
72.
go back to reference Cruz-Soto ME1, Scheiber MD, Gregerson KA, Boivin GP, Horseman ND. Pituitary tumorigenesis in prolactin gene-disrupted mice. Endocrinology. 2002;143:4429–4436. Cruz-Soto ME1, Scheiber MD, Gregerson KA, Boivin GP, Horseman ND. Pituitary tumorigenesis in prolactin gene-disrupted mice. Endocrinology. 2002;143:4429–4436.
73.
go back to reference Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, Iuvone PM, et al. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest. 2002;110:973–81.CrossRefPubMedPubMedCentral Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, Iuvone PM, et al. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest. 2002;110:973–81.CrossRefPubMedPubMedCentral
74.
go back to reference Asa SL, Kelly MA, Grandy DK, Low MJ. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology. 1999;140:5348–55.CrossRefPubMed Asa SL, Kelly MA, Grandy DK, Low MJ. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology. 1999;140:5348–55.CrossRefPubMed
75.
go back to reference Biondi M, Picardi A. Psychological stress and neuroendocrine function in humans; the last two decades of research. Psychoter and Psychosom. 1999;68:114–50.CrossRef Biondi M, Picardi A. Psychological stress and neuroendocrine function in humans; the last two decades of research. Psychoter and Psychosom. 1999;68:114–50.CrossRef
76.
go back to reference Sobrinho LG, Simoes M, Barbosa L, Raposo JF, Pratas S, Fernandes PL, et al. Cortisol, prolactin, growth hormone and neurovegetative responses to emotions elicited during an hypnoidal state. Psychoneuroendocrinology. 2003;28:1–17.CrossRefPubMed Sobrinho LG, Simoes M, Barbosa L, Raposo JF, Pratas S, Fernandes PL, et al. Cortisol, prolactin, growth hormone and neurovegetative responses to emotions elicited during an hypnoidal state. Psychoneuroendocrinology. 2003;28:1–17.CrossRefPubMed
77.
go back to reference Lennartsson AK, Jonsdottir IH. Prolactin in response to acute psychosocial stress in healthy men and women. Psychoneuroendocrinology. 2011;36:1530–9.CrossRefPubMed Lennartsson AK, Jonsdottir IH. Prolactin in response to acute psychosocial stress in healthy men and women. Psychoneuroendocrinology. 2011;36:1530–9.CrossRefPubMed
79.
go back to reference Wieschhoff HA. Artificial stimulation of lactation in primitive cultures. Bull Hist Med. 1940;8:1403–15. Wieschhoff HA. Artificial stimulation of lactation in primitive cultures. Bull Hist Med. 1940;8:1403–15.
80.
go back to reference Scarpa A. Etnomedicina. Milan: Franco Lucisano Editore; 1980. Scarpa A. Etnomedicina. Milan: Franco Lucisano Editore; 1980.
81.
go back to reference Reichlin S. Prolactin and growth hormone secretion in stress. In: Chrousos GP, Loriaux DL, Gold PW, editors. Mechanisms of physical and emotional stress. New York: Plenum Press; 1988. p. 353–76.CrossRef Reichlin S. Prolactin and growth hormone secretion in stress. In: Chrousos GP, Loriaux DL, Gold PW, editors. Mechanisms of physical and emotional stress. New York: Plenum Press; 1988. p. 353–76.CrossRef
82.
go back to reference Voith VL. Functional significance of pseudocyesis. Mod Vet Pract. 1980;61:75–7.PubMed Voith VL. Functional significance of pseudocyesis. Mod Vet Pract. 1980;61:75–7.PubMed
Metadata
Title
Prolactin and human weight disturbances: A puzzling and neglected association
Authors
Luis G. Sobrinho
Nelson D. Horseman
Publication date
01-06-2019
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 2/2019
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-019-09503-1

Other articles of this Issue 2/2019

Reviews in Endocrine and Metabolic Disorders 2/2019 Go to the issue